TNF and inflammatory bowel disease: Stratification by study group revealed that patients with IBD treated with anti-TNF had significantly lower frequencies of VH mutations in total S-specific MBCs compared to both the patients with IBD treated with anti-IL-12/23 and people in the healthy control group after the third dose of vaccine, with differences between the anti-IL-12/23 and anti-TNF groups also observed after dose 2 (Figure 6A).